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Abstract
Context—The botanical product silymarin, an extract of milk thistle, is commonly used by
patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy.
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Objective—To determine the effect of silymarin on liver disease activity in patients with chronic
hepatitis C virus (HCV) infection unsuccessfully treated with interferon-based therapy.
Design, Setting, and Participants—Multicenter, double-blind, placebo-controlled trial
conducted at 4 medical centers in the United States. Participants included 154 persons with
chronic HCV infection and serum alanine aminotransferase (ALT) levels of 65 U/L or greater who
were previously unsuccessfully treated with interferon-based therapy. Enrollment began in May
2008 and was completed in May 2010, with the last follow-up visit completed in March 2011.
Intervention—Participants were randomly assigned to receive 420-mg silymarin, 700-mg
silymarin, or matching placebo administered 3 times per day for 24 weeks.
Main Outcome Measures—The primary outcome measure was serum ALT level of 45 U/L or
less (considered within the normal range) or less than 65 U/L, provided this was at least a 50%
decline from baseline values. Secondary outcomes included changes in ALT levels, HCV RNA
levels, and quality-of-life measures.
Results—After 24 weeks of treatment, only 2 participants in each treatment group (P≥.99) met
the primary outcome measure (3.8% [95% CI, 0.5% to 13.2%] for placebo, 4.0% [95% CI, 0.5%
to 13.7%] for 420-mg silymarin, and 3.8% [95% CI, 0.5% to 13.2%] for 700-mg silymarin). The
mean decline in serum ALT activity at the end of treatment did not differ significantly (P=.75)
across the 3 treatment groups (mean decline, −4.3 [95% CI, −17.3 to 8.7] U/L for placebo, −14.4
[95% CI, −41.6 to 12.7] U/L for 420-mg silymarin, −11.3 [95% CI, −27.9 to 5.4] U/L for 700-mg
silymarin); there likewise were no significant differences in HCV RNA levels (mean change, 0.07
[95% CI, −0.05 to 0.18] log10 IU/mL for placebo, −0.03 [95% CI, −0.18 to 0.12] log10 IU/mL for
420-mg silymarin, 0.04 [95% CI, −0.08 to 0.16] log10 IU/mL for 700-mg silymarin; P=.54) or
quality-of-life measures. The adverse event profile of silymarin was comparable with that of
placebo.
Conclusion—Higher than customary doses of silymarin did not significantly reduce serum ALT
levels more than placebo in participants with chronic HCV infection unsuccessfully treated with
interferon-based therapy.
CHRONIC HEPATITIS C VIRUS (HCV) infection affects almost 3% of the global
population and may lead to cirrhosis, hepatic failure, and hepatocellular carcinoma.1
Sustained virological response can be achieved in patients treated with peginterferon and
ribavirin, often combined with an HCV protease inhibitor.2–4 Nevertheless, a large
proportion of patients do not respond to these therapies, and many others cannot be treated
because of medical comorbidities.5 Thus, alternative medications with disease-modifying
activity may be of benefit.
Silymarin (Silybum marianum), an extract of milk thistle, is the botanical treatment most
commonly used for liver disorders in the United States, owing to its purported
hepatoprotective properties.6,7 Indeed, 33% of patients with chronic HCV infection and
cirrhosis reported current or past use of silymarin for the treatment of their disease.8
Silymarin has been demonstrated to have anti-inflammatory and immunomodulatory
properties via inhibition of NF-κB (nuclear factor κ-light-chain-enhancer of activated B
cells), as demonstrated in vitro.9,10 Studies of silymarin in the HCV replicon system also
suggest an effect on HCV core and NS5A expression, although at high concentrations.11
These same pathways, implicated in the pathogenesis of chronic liver disease, provide the
rationale to investigate silymarin as a potential treatment for chronic HCV infection.
Clinical studies that have evaluated milk thistle for a variety of liver diseases have yielded
inconsistent results and were compromised by lack of well-defined efficacy end points,
heterogeneous populations of patients with liver disease, and use of nonstandardized
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silymarin preparations.12–16 In view of the limited data available on dosing and
pharmacokinetics of silymarin, an initial dose-ranging study was performed to identify
silymarin doses for further study in the current trial.17 Two doses, 3 and 5 times higher than
the customary dose, were selected based on this early testing. The aim of the present study
was to assess the safety and efficacy of silymarin for treating chronic HCV infection among
patients previously unsuccessfully treated with conventional interferon (IFN)–based
treatment.
METHODS
Trial Design
The Silymarin in NASH and C Hepatitis (SyNCH) study was a randomized, double-blind,
placebo-controlled multicenter trial of 2 doses of silymarin and placebo with 1:1:1 allocation
into the 3 treatment groups. Enrollment began in May 2008 and was completed in May
2010. Follow-up was completed by March 2011.18
Participants
Adult patients with chronic HCV infection were eligible for the trial if they had received
previous IFN-based therapy without sustained virological response, had quantifiable serum
HCV RNA levels, and had an alanine aminotransferase (ALT) level of 65 U/L or greater at
screening. Patients were excluded if they had evidence of decompensated hepatic cirrhosis, a
positive HIV antibody test result or positive result for HBsAg (surface antigen of the
hepatitis B virus), or had used milk thistle products within the previous 30 days. Liver
biopsy was not required for entry, although if obtained, the presence of moderate steatosis or
steato-hepatitis were considered exclusions.
Participants were recruited at 4 clinical centers in the United States (Beth Israel Deaconess
Medical Center, Boston, Massachusetts; Thomas Jefferson University, Philadelphia,
Pennsylvania; University of North Carolina, Chapel Hill; University of Pennsylvania,
Philadelphia). The study was approved by the institutional review boards at these centers
and the data coordinating center, and all participants provided written informed consent. An
independent data and safety monitoring board established by the National Institutes of
Health approved the protocol and regularly reviewed study progress.
Interventions
Participants were randomly assigned to 1 of 3 groups: 420-mg silymarin, 700-mg silymarin,
or matching placebo gelatin capsules administered 3 times daily for 24 weeks, a standard
duration of treatment for which effective therapies for HCV have regularly demonstrated
improvement in disease activity.5,18,19 The botanical product used in the trial is a dry extract
of milk thistle fruits (S marianum), marketed as Legalon 140 (Rottapharm | Madaus)
(eAppendix, available at http://www.jama.com). This standardized silymarin product is
approved as a prescription drug in several countries of Europe and Asia as a treatment for
hepatic disorders. The placebo gelatin capsules consisted of lactose and other Legalon 140
components that included mannitol, magnesium stearate, and sodium carboxymethyl starch.
The study was double blinded so that patients took 5 capsules 3 times daily, which consisted
of either 5 capsules of silymarin (700 mg), 3 capsules of silymarin and 2 of placebo (420
mg), or 5 capsules of placebo, provided in a sealed, labeled cup. Medication was dispensed
in the sealed cups, and each cup represented 1 dose.
Outcomes
The primary outcome measure for efficacy was serum ALT level of 45 U/L or less
(approximate normal range) or attainment of at least 50% decline of serum ALT level to less
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than 65 U/L (approximately 1.5 times the upper limit of normal) after the 24-week treatment
period. The change in serum ALT level was chosen as the primary outcome in this study as
a practical measure that has been correlated with improvement in hepatic necroinflammatory
activity during studies of interferon for HCV infection.18–22 Secondary outcomes included
change in serum ALT and serum HCV RNA levels during treatment. Adherence to study
medication was assessed by dose counts.
Adverse events were prospectively monitored, as were blood counts and results of chemistry
and coagulation tests. The Short-Form 36 and the Chronic Liver Disease Questionnaire were
used to measure generic and liver-disease related quality of life, respectively.23,24 The
Center for Epidemiologic Studies–Depression scale measured depressive
symptomatology.25 These instruments were completed by participants before, during, and at
the end of treatment. HCV RNA levels were measured by reverse transcription polymerase
chain reaction (Abbott RealTime HCV assay, Abbott Molecular Inc). Plasma specimens for
measurement of levels of silymarin flavonolignans, predominantly silybin A, were collected
during the trial and quantified by liquid chromatography electron spray ionization mass
spectrometry as previously described.17 Silybin A is the major silymarin flavonolignan
detected in blood.
Participants were seen at baseline and for 6 follow-up visits scheduled 2 to 8 weeks apart
throughout the 24-week treatment period, and at 4 and 12 weeks after treatment, to assess
safety and efficacy.
Sample Size
In the absence of silymarin, it was anticipated that 15% of participants in the placebo group
would reach the primary outcome measure during a 24-week period. A clinically significant
difference was considered to be 25%, ie, that 40% of those receiving silymarin met the
primary end point. These estimates were based on early studies conducted among patients
with HCV infection treated with interferon, placebo, or in observational control groups and
on the clinical experience of the investigators to account for the composite end point.19
Assuming no dose-response relationship and 40% success in each silymarin treatment
group, enrolling 153 patients (51 per group) would provide 80% power to reject the null
hypothesis at α=.05 using a χ2 test. If there was a dose-response relationship, there would
be greater power.
Randomization and Masking
Eligible participants were allocated to treatment group using an adaptive minimization
randomization scheme stratified by site and history of previous use of any milk thistle
preparations, using a web-based system created by the data coordinating center that
allocated treatment to minimize the imbalance in treatment allocation. The randomization
algorithm ensured that the treatment groups were imbalanced by no more than 4 participants
overall, by no more than 3 participants within each site, and by no more than 2 participants
within each stratum within each site, in that order. All clinical center personnel and
participants were masked to treatment assignment and the parameters of the allocation
scheme.
Statistical Methods
The analysis of the primary outcome measure was an intention-to-treat analysis including all
allocated participants. Preplanned secondary outcomes included changes in ALT and serum
HCV RNA levels, as well as quality-of-life and depression measures. Adherence to study
medication was measured using a summary of missed- dose information obtained from dose
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counts and calculated as a percentage of the medication dose cups dispensed to participants
compared with cups returned by participants at follow-up visits.
Baseline characteristics were summarized using frequencies and proportions for categorical
variables (eg, race, sex) and median and quartiles for continuous variables (eg, age, baseline
ALT levels). Because race and ethnicity have been shown to be associated with response to
IFN-based therapies,26 these data were collected using a self-report, fixed-category
questionnaire to evaluate their influence on the primary end point. Categorical variables
across treatment groups, including the primary outcome, were compared using Pearson χ2
test or its exact version when appropriate. The Kruskal-Wallis (non-parametric analysis of
variance) test was used to compare distributions of continuous measures across treatment
groups.
The primary outcome was summarized using percentages and 95% CIs. Secondary
outcomes (changes) were summarized using means and 95% CIs and compared across
treatment groups using the F test from the general linear model, with treatment as the only
explanatory factor in the model. Repeated ALT measures were analyzed by linear mixed
models with an autoregressive correlation structure, using ALT levels as the dependent
variable and treatment, time point, and treatment×time-point interaction as the independent
variables. The significance of the changes in ALT levels over time was assessed using a
likelihood ratio test of the interaction term.
The proportions of participants with serious adverse events between the treatment (either
silymarin dose) and placebo groups were compared using the Fisher exact test. In all
analyses, P=.05 was used as a cutoff for statistical significance. All null hypotheses were
tested against nondirectional alternatives.
Missing data for the primary end point and for the secondary end point of changes in ALT
level were handled using the last observation carried forward imputation method per the
external data and safety monitoring board. Analysis of the primary hypothesis was also
performed using multiple imputations. Twenty imputed data sets were created using a
Markov chain Monte Carlo algorithm based on the observed ALT values at previous time
points. For each of these imputed data sets, the primary end point was calculated and the
analysis was repeated. All analyses were performed using SAS version 9.2 (SAS Institute
Inc).
RESULTS
Of the 234 patients screened, 154 were randomly allocated to receive treatment. The most
frequent reason for ineligibility was serum ALT activity less than 65 U/L (Figure 1). Among
those enrolled, 86 (56%) had never used a milk thistle preparation (Figure 1).
Participants in the 3 treatment groups were similar with respect to baseline characteristics,
with the exception that the placebo group included a higher percentage of white participants
(Table 1). Most participants were men (71%); the median age was 54 years, and the median
body mass index was 29.2 (calculated as weight in kilograms divided by height in meters
squared). The majority of patients had HCV genotype 1 infection (91%). The median HCV
RNA level was 6.2 log10 IU/L and was similar in the 3 treatment groups. Serum ALT levels
did not differ significantly (median, 106 U/L for placebo; 110 U/L for 420-mg silymarin;
and 105 U/L for 700-mg silymarin; P=.90) across treatment groups. Markers suggestive of
advanced liver disease (serum bilirubin levels, albumin levels, platelet counts) did not differ
significantly across treatment groups.
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At the end of treatment, 5 participants achieved serum ALT activity less than 45 U/L; 1 in
the placebo group (1.9% [95% CI, 0.1% to 10.3%] and 2 each in the 420-mg silymarin
(4.0% [95% CI, 0.5% to 13.7%]) and 700-mg silymarin (3.8% [95% CI, 0.5% to 13.2%])
groups (P=.80) (Table 2). One other participant treated with placebo had a decrease of serum
ALT levels to less than 65 U/L, which reflected a decrease of 57% from baseline. Thus, 2
participants in each treatment group achieved the prespecified primary end point (P>.99).
The percentages of participants who achieved the primary end point were 3.8% (95% CI,
0.5% to 13.2%) in the placebo group, 4.0% (95% CI, 0.5% to 13.7%) in the 420-mg
silymarin group, and 3.8% (95% CI, 0.5% to 13.2%) in the 700-mg silymarin group.
When the multiple imputations method was used to handle missing data,27 the estimated
4.6%, 4.3%, and 3.8% of participants achieving the primary end point in the placebo, 420-
mg silymarin, and 700-mg silymarin groups, respectively (P=.89), were similar compared
with the estimates obtained using the last observation carried forward method, again
indicating that there was not a significant difference in the response across the 3 treatment
groups.
Furthermore, there was no statistically significant difference across treatment groups (P=.75)
when changes in serum ALT levels from baseline to end of treatment were analyzed as a
continuous variable (mean decline, −4.3 [95% CI, −17.3 to 8.7] U/L for placebo, −14.4
[95% CI, −41.6 to 12.7] U/L for 420-mg silymarin, and −11.3 [95% CI, −27.9 to 5.4] U/L
for 700-mg silymarin). Mean ALT levels are shown by treatment group for all participants
in an intention-to-treat analysis (Figure 2).
The change in serum ALT levels did not differ significantly across treatment groups in
either stratum defined by the presence (mean decline, −5.9 [95% CI, −20.9 to 9.0] U/L for
placebo, −16.6 [95% CI, −38.3 to 5.2] U/L for 420-mg silymarin, and −10.5 (95% CI, −32.1
to 11.1] U/L for 700-mg silymarin) or absence (mean decline, −2.9 [95% CI, −24.3 to 18.6]
U/L for placebo, −12.8 [95% CI, −59.8 to 34.2] U/L for 420-mg silymarin, and −11.8 [95%
CI, −37.0 to 13.4] U/L for 700-mg silymarin) of previous milk thistle use.
Mean serum HCV RNA levels did not change significantly during the 24 weeks of therapy
(mean change, 0.07 [95% CI, −0.05 to 0.18)] log10 IU/L for placebo, −0.03 [95% CI, −0.18
to 0.12] log10 IU/L for 420-mg silymarin, and 0.04 [95% CI, −0.08 to 0.16] log10 IU/L for
700-mg silymarin; P=.54) (Table 2). Similarly, restricting the analysis to patients from
whom all data were available throughout the treatment phase showed no differences
between the 3 treatment groups. Analysis of the continuum of HCV RNA levels from
baseline to end of treatment did not demonstrate a statistically significant difference.
Adherence was maintained throughout the study, with 95% of participants meeting or
exceeding an 80% threshold for adherence (91.8% for placebo, 95.2% for 420-mg silymarin,
and 93.0% for 700-mg silymarin). Analysis of serum ALT activity performed in a per-
protocol analysis (125 participants with >80% adherence) did not demonstrate significant
changes in serum ALT activity by week 24 of treatment (mean change, −8.3 [95% CI, −22.3
to 5.8] U/L for placebo, −17.6 [95% CI, −51.4 to 16.2] U/L for 420-mg silymarin, and −3.7
[95% CI, −17.0 to 9.6] U/L for 700-mg silymarin; P=.66).
Silybin A plasma concentrations in participants who completed the study, drawn randomly
at visits after a recorded dose, were observed in the range of 2.1 to 2048 ng/mL. All samples
from placebo recipients had no detectable silybin A concentrations. The median and highest
steady-state silybin A concentrations observed were 2-fold greater in the higher-dose group
compared with the lower-dose group.
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There were no significant changes in physical or mental health components of quality-of-life
scores (Short-Form 36), in chronic liver disease health-related quality-of-life assessments
(Chronic Liver Disease Questionnaire), or in depression scores (Center for Epidemiologic
Studies–Depression) in any group (Table 2).
Frequency of adverse events reported by individual patents did not differ significantly
among the treatment groups (Table 3), although the power to detect such differences was
limited because of the sample size and the relative infrequency of adverse events. The most
frequent adverse events were gastrointestinal symptoms, reported in 12% of participants
receiving any silymarin dose compared with 5% receiving placebo. The majority of adverse
events were reported as mild or moderate in severity. Three patients (1 in the 420-mg
silymarin group and 2 in the 700-mg silymarin group) had treatment discontinued because of
adverse events. There were 12 serious adverse events: 1 in the placebo group, 6 in the 420-
mg silymarin group, and 5 in the 700-mg silymarin group, reported by 2, 5, and 1 unique
patients, respectively. Comparing placebo vs silymarin (either dose), the proportion of
patients with at least 1 serious adverse event in the silymarin groups (7/102) did not differ
significantly from the proportion in the placebo group (1/52) (P = .27). One participant
treated with 420-mg silymarin died as a result of suicide 12 weeks after finishing treatment.
COMMENT
Milk thistle fruit extracts have been widely used in the setting of liver disease, but rigorous
trials have not been conducted. The current study was designed to assess the efficacy of
increasing doses of silymarin in patients with chronic HCV infection. We found that
silymarin did not significantly improve serum ALT levels compared with placebo when
administered to patients with chronic HCV infection previously unsuccessfully treated with
IFN-based therapy.
This trial of silymarin is unique in that it used a well-characterized silymarin product;
focused on a specific liver disease; enrolled a large, representative cohort across 4 different
clinical sites; included an adequate treatment duration (24 weeks); had excellent adherence
with study medication and visits; and used well-defined outcome measures.
Limited data from human and animal studies suggest that silymarin flavonolignans undergo
rapid and extensive conjugative metabolism with primarily biliary excretion, resulting in
short half-lives and low systemic exposures following oral administration of silymarin.28–32
The doses adminis tered in the present trial, substantially higher than customary doses of
silymarin preparations, were first evaluated in a phase 1 pharmacokinetic study and were
chosen to increase the chance of detecting a therapeutic benefit. Steady-state peak plasma
concentrations of silybin A, the major silymarin flavonolignan detected in blood, ranged
between 77 ng/mL to 1510 ng/mL at doses of 280 to 700 mg administered every 8 hours,
similar to concentrations achieved in the current trial.17 In contrast, the antiviral, anti-
inflammatory, and antioxidant properties of silymarin have been demonstrated in human
HCV replicon systems, human hepatoma cell lines, and primary human hepatocytes using
silybin A concentrations between 20 and 50 μg/mL, markedly higher than the peak
concentrations achieved with the oral silymarin preparation in this study.9,11,33–36
Because the focus of this study was on modifying disease activity, serum ALT level was
deemed the most appropriate measure of the primary outcome, rather than HCV RNA level,
which was explored as a secondary outcome. Although it is acknowledged that the most
direct measure of improvement in liver disease is obtained by assessing paired liver biopsies
obtained before and after therapy, liver biopsies incur risks to participants. As noted above,
decreases in serum ALT levels highly correlate with improvement in hepatic
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necroinflammatory activity after interferon therapy, even when HCV RNA levels remain
unchanged.19–22 Thus, in the absence of any change in serum ALT level, improvement in
hepatic histology or in hepatic fibrosis (as measured by noninvasive serum markers or
transient elastography, none of which are approved by the US Food and Drug
Administration in the United States37) would have been unlikely.
Serum HCV RNA levels also remained unchanged during the course of this study, which
was consistent with the primary end point findings for disease activity. It is interesting,
however, that a recent case series of patients with treatment-resistant HCV infection showed
up to 3-log reductions in HCV RNA levels when treated with infusions of silibinin
succinate, a silymarin-derived compound not contained in the oral product used in this
trial.38 Serum ALT activity was also improved in some patients. Differential in vitro effects
on HCV viral genotypes and HCV RNA–dependent RNA polymerase between oral
silymarin and silibinin succinate have also been reported, suggesting potential differential in
vivo activities of the 2 formulations.34,35
Adherence to therapy was well maintained, despite a high pill burden, throughout the 24-
week treatment period. Analysis of the primary end point among participants with the
highest level of adherence did not demonstrate any significant difference across treatment
groups. Similarly, an analysis of continuous changes in serum ALT levels during the first or
second 12 weeks of treatment could not differentiate any treatment effect.
This study had several limitations. Fewer patients than expected treated with placebo or
silymarin achieved the primary outcome, raising the possibility that the participants in this
study were not representative of all patients with chronic HCV not responding to IFN-based
therapy or that the expected response rates were assumed to be higher than the actual rates in
the population. Enrollment in this study required an abnormal ALT level, which would
identify the population for whom an alternative medication would be expected to provide the
greatest benefit if any signal of efficacy was detected. Furthermore, the study was designed
to have adequate power if 25% more participants in the treatment group had a response than
in the placebo group. Even if the actual response in the placebo group was as low as the
observed response (3.8%), the study was still adequately powered to find the hypothesized
difference between the treated and placebo groups. If the true response rate in the placebo
group was 3.8% and was 25% higher (28.8%) in the 2 silymarin groups, the study would
have 91% power to detect a 25% between-group difference at the same sample size and type
I error level.
Although the percentage of participants with serious adverse events was numerically higher
with silymarin treatment, the distribution of all adverse events was similar between the
treatment and placebo groups. However, this study was not powered to find statistically
significant differences among treatment groups with respect to adverse events.
In summary, oral silymarin, used at higher than customary doses, did not significantly alter
biochemical or virological markers of disease activity in patients with chronic HCV
infection who had prior treatment with IFN-based regimens. Silymarin did not provide
greater benefit than placebo for patients with treatment-resistant chronic HCV infection.
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Figure 1.
Study Flow
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Figure 2.
Mean ALT Levels Across Time by Treatment Group for All Participants
Means estimated by fitting a linear mixed model with alanine aminotransferase (ALT) as
outcome and treatment group and time point (treated as categorical) and their interaction as
covariates. Dotted line at y=45 U/L indicates the ALT value considered the upper limit of
normal for this study. Time axis has been shifted slightly to the right by 0.3 units for 420-mg
silymarin and 0.6 units for 700-mg silymarin to separate the error bars. Error bars indicate
95% CIs.
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Table 1
Baseline Characteristics of Study Participants
Silymarin
Characteristics All (N = 154) Placebo (n = 52) 420 mg (n = 50) 700 mg (n = 52) P Value
a
Age, median (IQR), y 54.0 (51.0–58.0) 56.0 (51.5–59.5) 54.0 (52.0–57.0) 54.0 (48.0–58.0) .31
Men, No. (%) 110 (71.4) 41 (78.9) 34 (68.0) 35 (67.3) .35
Race/ethnicity, No. (%)
b
 White 114 (75.0) 45 (88.2) 36 (72.0) 33 (64.7)
.08 Black 31 (20.4) 5 (9.8) 11 (22.0) 15 (29.4)
 Other 7 (4.6) 1 (2.0) 3 (6.0) 3 (5.9)
 Hispanic 8 (5.2) 3 (5.8) 3 (6.0) 2 (3.9) .91
c
Body mass index, median (IQR)
d
29.2 (26.5–32.7)
e
29.1 (25.6–32.7)
e 28.5 (26.0–32.4) 30.2 (28.1–32.9) .29
History of diabetes, No. (%) 21 (13.6) 8 (15.4) 6 (12.0) 7 (13.5) .88
History of any milk thistle
preparation use, No. (%) 68 24 (46.2) 22 (44.0) 22 (42.3) .92
HCV genotype, No. (%)
 1 139 (91.5) 44 (88.0) 47 (94.0) 48 (92.3)
.59
c
 2, 3, or 4 13 (8.5) 6 (12.0) 3 (6.0) 4 (7.7)
HCV RNA, median (IQR), log10 IU/
L 6.2 (5.8–6.6)
e 6.4 (5.9–6.7) 6.1 (5.7–6.5) 6.3 (5.8–6.6)e .18
Albumin, median (IQR), g/dL 4.2 (3.9–4.4)
e
4.3 (3.9–4.5)
e 4.1 (3.9–4.4) 4.1 (4.0–4.4) .37
ALT, median (IQR), U/L 107.0 (83.0–150.0) 106.0 (83.0–136.0) 109.5 (83.0–158.0) 104.5 (83.5–151.0) .9
Creatinine, median (IQR), mg/dL 0.8 (0.7–1.0) 0.9 (0.7–1.0) 0.8 (0.7–1.0) 0.8 (0.8–1.0) .75
Fasting glucose, median (IQR), mg/
dL 93.0 (83.0–105.0)
f
91.5 (80.0–106.0)
g
93.0 (83.0–103.0)
h
93.0 (83.0–113.0)
h .75
Hemoglobin, median (IQR), g/dL 15.0 (14.2–15.8) 15.2 (14.2–15.9) 15.0 (14.1–15.6) 15.0 (14.2–15.9) .72
Platelets, median (IQR), ×103 cells/
μL 177.0 (133.0–217.0) 180.0 (138.5–228.0) 173.0 (132.0–227.0) 177.0 (134.0–206.5) .98
Total bilirubin, median (IQR), mg/
dL 0.8 (0.6–1.0) 0.9 (0.6–1.1) 0.8 (0.6–1.0) 0.8 (0.6–1.0) .85
White blood cells, median (IQR),
cells/μL 5700 (4700–6900) 5800 (4900–6900) 5500 (4600–6500) 5600 (4900–7100) .47
SF-36 score, median (IQR)
i
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Silymarin
Characteristics All (N = 154) Placebo (n = 52) 420 mg (n = 50) 700 mg (n = 52) P Value
a
 Physical health composite 51.0 (43.0–55.0)
e 51.0 (43.0–53.5) 52.0 (45.0–56.0)e 48.5 (42.0–54.0) .13
 Mental health composite 54.0 (47.0–57.0)
e 54.0 (47.55–8.0) 53.0 (47.0–57.0)e 54.0 (45.0–57.0) .74
CLDQ score, median (IQR)
i
5.8 (5.1–6.3)
e 5.8 (5.1–6.3) 6.0 (5.4–6.4)e 5.7 (4.8–6.3) .25
CES-D score, median (IQR)
i
8.0 (3.0–14.0)
e 7.5 (3.0–14.0) 8 (3–13.7) 8.5 (5.0–16.0)e .68
Abbreviations: ALT, alanine aminotransferase; CES-D, Center for Epidemiologic Studies–Depression Scale; CLDQ, Chronic Liver Disease
Questionnaire; HCV, hepatitis C virus; IQR, interquartile range; SF-36, Short-Form 36.
SI conversion factors; To convert ALT values to μkat/L, multiply by 0.0167; creatinine values to μmol/L, multiply by 88.4; glucose values to
mmol/L, multiply by 0.0555.
a
P values are for testing equality across all 3 groups: Kruskal-Wallis test for continuous data (presented by median and IQR) and Pearson χ2 test
for categorical data (presented by No. [%]) except otherwise indicated.
b
Data missing for 2 participants.
c
By exact Pearson χ2 test.
d
Calculated as weight in kilograms divided by height in meters squared.
e
One patient missing data.
f
Twelve patients missing data.
g
Six patients missing data.
h
Three patients missing data.
i
SF-36 summary scores for the physical health composite range from 8 to 73 and for the mental health composite range from 10 to 74. CLDQ
scores range from 1 (most impairment) to 7 (least impairment). CES-D total scores range from 0 to 60, with higher scores indicative of more severe
depressive symptoms.
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Table 2
Analysis of Primary and Secondary Outcome Measures
Silymarin
Variable Placebo (n = 52) 420 mg (n = 50) 700 mg (n = 52) P Value
Primary end point, No. (%) [95% CI]
ALT ≤45 U/L at treatment wk 24
a 1 (1.9) [0.1 to 10.3] 2 (4.0) [0.5 to 13.7] 2 (3.8) [0.5 to 13.2] .80b
At least 50% ALT decline from baseline to wk 24
and ALT <65 U/L at treatment wk 24
a,c 2 (3.8) [0.5 to 13.2] 1 (2.0) [0.1 to 10.7] 2 (3.8) [0.5 to 13.2] .83b
Either treatment response 2 (3.8) [0.5 to 13.2] 2 (4.0) [0.5 to 13.7] 2 (3.8) [0.5 to 13.2] >.99
b
Secondary end points, mean (95% CI) 
d
Change in ALT, U/L −4.3 (−17.3 to 8.7) −14.4 (−41.6 to 12.7) −11.3 (−27.9 to 5.4) .75
e
Change in HCV RNA, mean, log10 IU/L 0.07 (−0.05 to 0.18)
f
−0.03 (−0.18 to 0.12)
g
0.04 (−0.08 to 0.16)
h
0.54
e
Quality of life
i
 SF-36
  Aggregate physical −0.69 (−2.78 to 1.39)
j
−2.86 (−5.06 to −0.66)
k
−0.27 (−2.24 to 1.69)
l
.18
e
  Aggregate mental 0.24 (−1.74 to 2.23)
j
0.35 (−2.10 to 2.80)
k
−0.90 (−3.35 to 1.53)
l
.68
e
 CLDQ 0.12 (−0.03 to 0.28)
m
−0.10 (−0.32 to 0.12)
k
−0.03 (−0.26 to 0.20)
l
.26
e
 CES-D −0.26 (−1.79 to 1.27)
m
−0.73 (−2.98 to 1.51)
k
−0.41 (−4.22 to 3.39)
l
.97
e
Abbreviations: ALT, alanine aminotransferase; CES-D, Center for Epidemiologic Studies–Depression; CLDQ, Chronic Liver Disease
Questionnaire; HCV, hepatitis C virus; SF-36, Short-Form 36.
SI conversion factor: To convert ALT values to to μkat/L, multiply by 0.0167.
a
Last ALT value prior to dropout was used in subsequent calculations for patients who dropped out (n = 16) prior to week 24 of treatment.
b
By exact χ2 test for testing the proportions across treatment groups.
c
One patient's ALT level was not measured at baseline; the last screening value was used in the calculation.
d
Change is calculated as week 24 value minus the baseline value; therefore, a negative value will indicate a decline. A negative change in ALT
level, HCV RNA level, and CES-D score, and a positive change in SF-36 and CLDQ scores, indicates improvement from baseline.
e
F test from general linear model was used to test the equality of mean changes across treatment groups.
f
Four patients missing the corresponding outcome measure.
g
Six patients missing the corresponding outcome measure.
h
Ten patients missing the corresponding outcome measure.
i
SF-36 scores range from 0–100 (higher scores indicate better functioning; US population has a score of 50). CLDQ scores range from 1 (most
impairment) to 7 (least impairment). CES-D total scores range from 0 to 60, with higher scores indicative of more severe depressive symptoms.
j
Three patients missing the corresponding outcome measure.
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k
Seven patients missing the corresponding outcome measure.
l
Eight patients patients missing the corresponding outcome measure.
m
Two patients missing the corresponding outcome measure.
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Table 3
Number of Adverse Events and Serious Adverse Events by Treatment Group
No.
Silymarin
Events Placebo 420 mg 700 mg P Value
a
Participants with any adverse event
 All adverse events 34 31 29 .84
 Serious adverse events 1 6 5 .08
 Most common classes of adverse events
  Gastrointestinal 4 8 6 .56
  Musculoskeletal 4 2 3 .70
  Dermatologic 3 0 4 .67
  Infection 3 1 3 .44
  Physical injury 1 1 3 .65
  Other 19 19 10 .17
Participants with ≤1 adverse event
 All adverse events 21 17 17 .68
 Serious adverse events 1 5 2 .10
 Most common classes of adverse events
  Gastrointestinal 3 6 6 .56
  Musculoskeletal 4 2 3 .91
  Dermatologic 3 0 4 .22
  Infection 3 1 2 .87
  Physical injury 1 1 2 >.99
  Other 13 12 6 .18
a
For comparing number of adverse events across doses, a repeated-measure generalized linear model was used to assess statistical significance. For
comparing proportion of patients with at least 1 adverse event across doses, exact Pearson χ2 test was used to assess statistical significance.
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